The roughly 900 basis point recovery from the 38.8% trough in 2025Q2 suggests the merger-related inventory step-up charges have largely rolled off, and the 2027Q1 gross base sits essentially at the 47.9% level reported in 2024Q4, so pricing power on the diagnostic consumable franchise appears intact. However, SG&A has consumed an estimated 87% to 148% of gross profit across the trailing ten quarters, leaving operating income at breakeven or worse in six of the last eight reported periods; if integration costs were genuinely transitional, operating leverage should already be visible, and its continued absence would suggest the cost structure is more structural than the market's 38.58x forward earnings multiple appears to assume.

Set against IDEXX's 42.5% ROIC and 72% ROE, Neogen's profile is not a cyclical dip but a multi-year failure to earn a return on the capital deployed into the Food Safety acquisition. Two adjustments warrant caution: if ROIC is computed on invested capital including the approximately $1.0 billion of remaining goodwill, the near-zero reading partly reflects acquisition accounting rather than operating performance, and a goodwill-excluded measure would be the more meaningful test of whether the underlying business earns its cost of capital. Equally, equity has contracted from $3.1 billion to about $2.1 billion through impairment charges, so ROE and ROIC could rebound mechanically once reported net income turns positive without any genuine improvement in return generation; investors should monitor the numerator's quality, not just the ratio's direction.

DSO has held near 58 days throughout, while DPO lengthened from 45 to 61 days over the same window, suggesting Neogen is extracting more supplier financing than it was pre-merger, which supports cash flow but may signal negotiating pressure on smaller vendor counterparties. The more consequential efficiency metric is asset turnover, reported at 0.07x quarterly and roughly 0.27x annualized, versus an implied annualized turnover near 1.7x for IDEXX derived from its 72% ROE, 24.6% net margin and 0.67 debt-to-equity. Because goodwill and acquired intangibles inflate Neogen's asset base, a turnover measure calculated on net property, plant and equipment of about $349 million would present a materially different picture, so the depressed headline turnover should be interpreted as an artifact of the balance sheet structure as much as an operational shortfall.

The direction of travel is favorable: debt-to-equity improved from 0.44 to 0.37 and absolute debt fell by approximately $138 million over the period, while the current ratio of 3.90 and quick ratio of 2.92 imply substantial refinancing flexibility relative to diagnostic peers such as QuidelOrtho at 1.48 debt-to-equity. However, interest coverage has been violently unstable, ranging from -35.85 to +3.66 across the last ten quarters with a -0.46 reading in 2026Q3 and -0.08 in 2027Q1, so the coverage ratio currently conveys more about the accounting distortion in EBITDA than about genuine debt service comfort. Cash of about $172 million represents only around 22% of outstanding debt, and the roughly 47-day gap between the current and quick ratios signals that liquidity is materially inventory-dependent, leaving suppliers' willingness to extend terms as a key variable; covenant headroom and refinancing maturities cannot be assessed from the data provided and warrant further investigation.

The trailing P/E of -292x is analytically meaningless and confirms that current earnings cannot anchor valuation, so the meaningful anchors are the 2.92x price-to-sales and 1.21x price-to-book; for context, IDEXX's P/E and 24.6% net margin imply a price-to-sales multiple near 9.5x, suggesting Neogen trades at roughly a third of that revenue multiple but also without any demonstrated earnings stream. The forward multiple is built on a consensus EPS estimate that has risen from $0.05 to $0.08 despite no company guidance being reissued, which means the implied recovery from a -0.8% operating margin to sustainable profitability is steep and unverified. Price-to-free-cash-flow of 17.18x looks reasonable in isolation, but free cash flow margin has swung from -26.0% to +19.3% on working capital movements and cumulative free cash flow over the ten-quarter window is negative, so that multiple is likely an artifact of a favorable collection quarter rather than a durable cash generation profile.